SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Wedbush Cuts Perspective Therapeutics Price Target to $9, Keeps Outperform

Wedbush lowered its price target to $9 from $11 while maintaining an Outperform rating.

CATX

Related stories